Summarized by Masters of Longevity from Longevity Technology.
A short news article about early clinical data for a topical anti-senescence treatment, previewing trial design, biomarkers, and intriguing systemic signals.
Key Takeaways
- Topical RLS-1496 reduced measured skin epigenetic age by an average of 2.1 years versus each patient’s baseline.
- Biopsies showed reduced senescence-associated signatures and a 10% increase in type III collagen fibers after treatment.
- Plasma proteomics identified a 17% fall in CCL22 by Day 36 in treated patients while vehicle-treated patients showed a 19% increase.
